Lentiviral delivered aflibercept Oxford Biomedica-203 for treatment of neovascular AMD
September 2023
Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy
December 2004
Hsp40 Molecules That Target to the Ubiquitin-proteasome System Decrease Inclusion Formation in Models of Polyglutamine Disease
June 2007
Global Manufacturing of CAR T Cell Therapy
21st December 2016
Gene Therapy for Parkinson’s Disease: Preclinical Evaluation of Optimally Configured TH:CH1 Fusion for Maximal Dopamine Synthesis
8th July 2019
Start with Stable. Stepping onto TetraVecta Packaging Cells to Make a Clearer Pathway to LentiStable™ Producer Cell Lines
Rapid Optimisations for Cell & Gene Therapy Application
PKC Agonists as Small Molecule Inducing Agents for Enhancing Lentiviral Vector Production
Leveraging Automation in Analytical Analysis of Viral Vectors
Lentiviral Vector Capture using Anion-Exchange Chromatography. Removing an Industry Bottleneck through Rational Design
Introducing the CAZL Element: A Minimal 3′ UTR Sequence that Imparts Enhanced Expression to Transgenes in Target Cells
Further Development of the TRiP™ System: A Transgene Repression Technology Enhancing Lentiviral and AAV Vector Production
